soliqua

Soliqua Beats Basal Insulin for HbA1c Reduction Regardless of Level at Screening

Posted on

June 13, 2017






The Part 3 trial compared the effectiveness of Soliqua 100/33 and insulin glargine 100 Models/mL in 736 patients




After 30 weeks of remedy, Soliqua 100/33 (insulin glargine + lixisenatide injection; Sanofi) lowered HbA1C by 1.09–2.41% in patients with sort 2 diabetes (T2D) beforehand handled with 15–40 Models of basal insulin day by day. Knowledge from the post-hoc evaluation of the LixiLan-L Part three research have been introduced at the American Diabetes Association 77th Scientific Session, San Diego, CA.

The LixiLan-L Part three trial in contrast the effectiveness of Soliqua 100/33 and insulin glargine 100 Models/mL in 736 patients whose T2D was not adequately controlled at screening on 15–40 models of basal insulin every day, alone or mixed with one or two oral anti-diabetic brokers. The post-hoc evaluation included 660 patients who completed the 30-week research period and grouped patients by HbA1C degree at screening: HbA1c ≤eight%, HbA1c >8% to ≤9%, and HbA1c >9%. 

Other articles you might like;

Leave a Reply

Your email address will not be published. Required fields are marked *